Description

GLP2 Tirz — Dual Receptor Peptide for Advanced Metabolic Research

GLP2-Tirz 30mg, commonly referenced in research settings as GLP2-Tirz, is a synthetic dual agonist peptide engineered to interact with both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor pathways. This dual-incretin mechanism distinguishes GLP2-Tirz from traditional single-pathway peptides, making it a focal point of investigation in modern metabolic and endocrine research models.

At Crownwell Research, GLP2-Tirz is offered strictly for laboratory research applications, with emphasis on purity, analytical consistency, and reproducibility. Each batch is subjected to rigorous third-party verification methods, including HPLC and mass spectrometry, ensuring high-quality material suitable for controlled experimental use.

Mechanism of Action in Research Models

GLP2-Tirz’s defining characteristic is its dual agonism, targeting:

• GLP-1 receptors — commonly studied for their role in glucose signaling pathways
• GIP receptors — investigated for their involvement in metabolic regulation and energy balance

This combined receptor activity enables researchers to explore synergistic signaling effects that are not achievable through single agonist peptides alone.

In experimental settings, GLP2-Tirz is frequently utilized to examine:

• Multi-pathway metabolic signaling
• Hormonal interaction dynamics
• Receptor co-activation effects
• Downstream peptide signaling cascades

Its structural design allows for prolonged receptor engagement, making it particularly valuable in longitudinal or time-dependent studies.

Research Applications of GLP2-Tirz

GLP2-Tirz is widely incorporated into advanced laboratory investigations focusing on:

• Metabolic pathway modeling
• Endocrine system research
• Peptide-receptor interaction studies
• Signal transduction analysis
• Comparative peptide efficacy frameworks

Due to its dual-incretin functionality, GLP2-Tirz serves as a powerful comparative compound when analyzed alongside other peptides such as:

• GLP-1 receptor agonists
• GIP receptor signaling

This makes it particularly relevant for researchers aiming to evaluate multi-receptor targeting strategies.

Structural Characteristics

GLP2-Tirz is a synthetic peptide composed of a modified amino acid sequence designed to optimize receptor binding affinity and stability. Key structural attributes include:

• Enhanced resistance to enzymatic degradation
• Prolonged half-life in controlled environments
• Optimized receptor-binding domains
• Fatty acid modification to extend activity duration

These features contribute to its growing relevance in peptide-based research frameworks.

Purity, Testing, and Quality Assurance

At Crownwell Research, GLP2-Tirz is produced and validated under strict analytical standards:

• Purity: ≥99% (validated via HPLC)
• Verification: Mass spectrometry (MS) confirmation
• Consistency: Batch-level quality control
• Documentation: Certificate of Analysis (COA) available for each lot

Each vial is prepared for research handling and packaged to maintain compound integrity during storage and transport.

Why Researchers Choose GLP2-Tirz

Researchers prioritize GLP2-Tirz for its:

• Dual receptor engagement (GLP-1 + GIP)
• Advanced metabolic pathway relevance
• Stability in controlled experimental environments
• Versatility across multiple research domains

Its ability to bridge multiple signaling pathways makes it a cornerstone peptide for cutting-edge metabolic investigations.